NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2020, Vol. 32 ›› Issue (2): 209-223.doi: 10.16333/j.1001-6880.2020.2.005

• Article • Previous Articles     Next Articles

Study on the mechanism of Danshen-Gegen in treating coronary heart disease based on network pharmacology

MA Yang1,2,WANG Wen-jun1,2,HUANG Shao-jie2,LEI Lu2,WANG Kai1,2,FENG Xiao-na2,DING Yi2*,WEN Ai-dong1,2*   

  1. 1School of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 710042,China; 2The First Affiliated Hospital of Air Force Medical University,Xi’an 710032,China
  • Online:2020-02-29 Published:2020-04-23

Abstract: To explore the mechanism of action of Danshen-Gegen on coronary heart disease.Using network pharmacology,the first system in Chinese medicine pharmacological analysis platform for Danshen-Gegen active ingredients and targets,and then in the TDD,DrugBank and Disgenet database for coronary heart disease targets,the use of network pharmacology analysis software and related database for target protein interaction network (PPI),enrichment of target analysis and active ingredients-targets-pathway network construction.The results showed that 61 active ingredients and 68 mutual targets were screened from Danshen-Gegen.GO analysis showed that Danshen-Gegen root was involved in the transcription and inflammation of RNA polymerase II promoter and other biological processes,and targets were mainly concentrated in the extracellular space.The results of KEGG analysis showed that the regulation of Danshen-Gegen included signaling pathways such as HIF-10,PI3K-Akt,TNF and Jak-STAT.Above all,some active ingredients of Danshen-Gegen,such as tanshinone ⅡA,mignonette and puerarin,play a role of regulate blood pressure,angiogenesis and inflammation by affecting HIF-10,PI3K-Akt,TNF and Jak-STAT signal pathway.These pathways are primarily associated with the common targets of TNF,VEGFA,TP53 and IL6.Results of this study provide a reference for further study of the pharmacological effects of Danshen-Gegen.

Key words: network pharmacology, coronary heart disease, danshen-gegen, mechanism of action

CLC Number: